For the quarter ending 2025-09-30, TECX had -$18,461K decrease in cash & cash equivalents over the period. -$17,996K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,035 | -35,890 |
| Depreciation and amortization expense | 342 | 700 |
| Stock-based compensation expense | 2,817 | 4,691 |
| Loss on sale of property and equipment | -93 | -60 |
| Reduction in the carrying amount of the operating right-of-use assets | 535 | 1,035 |
| Change in fair value of safe liabilities | 0 | 0 |
| Prepaid expenses and other current assets | 753 | -2,151 |
| Othernon-currentassets | 5 | -8 |
| Accounts payable | -1,262 | 1,721 |
| Accrued expenses and other current liabilities | 34 | -1,157 |
| Operating lease liabilities | -581 | -1,121 |
| Net cash used in operating activities | -17,815 | -27,802 |
| Purchase of property and equipment | 181 | 27 |
| Proceeds from the sale of property and equipment | 15 | 55 |
| Net cash used in investing activities | -166 | 28 |
| Proceeds from the private placement, net of offering costs of 11,928 | 0 | 173,098 |
| Proceeds from the subscription agreement, net of offering costs of 2,000 | 0 | 0 |
| Cash acquired in connection with the merger, net of transaction costs of 7,412 | 0 | 0 |
| Proceeds from the exercise of stock options | 6 | 1,166 |
| Payment of withholding taxes related to stock-based compensation | 0 | 17 |
| Payment of deferred offering costs | -340 | -55 |
| Repayment of finance lease obligations | 123 | 239 |
| Net cash provided by financing activities | -457 | 173,953 |
| Effect of exchange rate changes on cash and cash equivalents | -23 | -37 |
| Net increase in cash and cash equivalents and restricted cash | -18,461 | 146,142 |
| Cash and cash equivalents at beginning of period | 141,826 | - |
| Cash and cash equivalents at end of period | 269,507 | - |
Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic, Inc. (TECX)